Beclabuvir

Summary

Beclabuvir (CHEMBL4105584) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including hepatitis c virus infection and chronic hepatitis c virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 18
• Chemistry: 659.8 Da · C36H45N5O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4105584
Name	Beclabuvir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	56934415
Molecular formula	C36H45N5O5S
Molecular weight	659.8
InChIKey	ZTTKEBYSXUCBSE-QDFUAKMASA-N

SMILES: CN1C[C@H]2CC[C@@H](C1)N2C(=O)[C@]34C[C@H]3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8

IUPAC name: (8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-[(1S,5R)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl]-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide

Also known as: Beclabuvir, BMS-791325, BECLABUVIR, NA

Parent form; salt/anhydrous children: CHEMBL6067983

Patent coverage: 60 distinct patent families (94 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 80 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
chronic hepatitis C virus infection	2	MONDO:0005354	EFO:0004220

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE1	10
PHASE3	3
PHASE2	3
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01973049	PHASE3	COMPLETED	UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
NCT01979939	PHASE3	COMPLETED	UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
NCT02170727	PHASE3	COMPLETED	A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
NCT00664625	PHASE1/PHASE2	COMPLETED	A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
NCT01193361	PHASE2	COMPLETED	Ph IIA Study (SOC +/- NS5B)
NCT01455090	PHASE2	COMPLETED	Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
NCT02175966	PHASE2	COMPLETED	Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
NCT00947245	PHASE1	WITHDRAWN	Japanese Bridging Study Conducted in the United States
NCT00996879	PHASE1	COMPLETED	Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
NCT02045693	PHASE1	COMPLETED	Drug Interaction & Methadone & Buprenorphine
NCT02045966	PHASE1	COMPLETED	Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
NCT02084953	PHASE1	COMPLETED	Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects
NCT02103569	PHASE1	COMPLETED	Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325
NCT02104843	PHASE1	COMPLETED	Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin
NCT02108639	PHASE1	COMPLETED	To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet
NCT02112110	PHASE1	COMPLETED	Absolute Bioavailability of BMS-791325
NCT02175602	PHASE1	COMPLETED	Study of Drug Combination on Pharmacokinetics in Healthy Volunteers
NCT02098616	Not specified	COMPLETED	Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).